Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Ligand Pharmaceuticals (NasdaqNM:LGND)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options
Location
10275 Science Center Drive
San Diego, CA 92121
Phone: (858) 550-7500
Fax: (858) 550-1826
Email: investors@ligand.com
Employees (last reported count): 356
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 23%
·Over the last 6 months:
 · 3 insider buys; 15.0K shares (0.1% of insider shares)
·Institutional: 28% (36% of float)
(172 institutions)
·Net Inst. Buying: 994.0K shares (+5.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, men's and women's health and skin diseases, as well as osteoporosis, metabolic, cardiovascular and inflammatory diseases. The Company strives to develop drugs that are more effective and/or safer than existing therapies and that are more convenient (taken orally or topically administered) and cost effective. Ligand markets four oncology products in the United States, Panretin gel, ONTAK, Targretin capsules and Targretin gel. Ligand is developing additional products through its internal development programs and has various products in clinical development, including products for larger market indications such as Non-small cell lung cancer, B-cell Non-Hodgkin's lymphoma, psoriasis and rheumatoid arthritis.
More from Market Guide: Expanded Business Description

Financial Summary
LGND discovers, develops and markets new drugs that address critical unmet medical needs of patients in areas of cancer, men's and women's health and skin diseases, as well as osteoporosis, cardiovascular and inflammatory diseases. For the six months ended 6/30/01, revenues rose 67% to $34.5 million. Net loss before acct. change fell 33% to $22.2 million. Revenues reflect higher sales of ONTAK. Lower loss were partially offset by higher selling and marketing exp.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

David Robinson, 52
Chairman, Pres, CEO
$556K
Paul Maier, 53
CFO, Sr. VP
250K
William Pettit, 51
Sr. VP- HR and Admin.
--  
Andres Negro-Vilar, M.D., Ph.D., 61
Sr. VP, R&D and CSO
397K
Steven Reich, Ph.D., 55
Sr. VP- Clinical Research
286K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:LGNDAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$7.813
Recent Price$10.25 
52-Week High
on 24-Oct-2000
$16.313
Beta1.62 
Daily Volume (3-month avg)157.6K
Daily Volume (10-day avg)129.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-23.4%
52-Week Change
relative to S&P500
+2.8%
Share-Related Items
Market Capitalization$612.0M
Shares Outstanding59.7M
Float46.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)-$0.77 
Earnings (ttm)-$0.84 
Earnings (mrq)-$0.18 
Sales (ttm)$1.07 
Cash (mrq)$0.77 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)9.58 
Income Statements
Sales (ttm)$61.9M
EBITDA (ttm)-$29.1M
Income available to common (ttm)-$48.2M
Profitability
Profit Margin (ttm)-78.0%
Operating Margin (ttm)-57.9%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-39.70%
Return on EquityN/A 
Financial Strength
Current Ratio (mrq)2.26 
Debt/EquityN/A 
Total Cash (mrq)$45.6M
Short Interest
As of 8-Aug-2001
Shares Short616.0K
Percent of Float1.3%
Shares Short
(Prior Month)
608.0K
Short Ratio4.67 
Daily Volume132.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.